Adjuvant chemotherapy in 780 patients with early breast cancer: 10-Year data from Saudi Arabia

Medical Oncology

Volumn 22, Issue 4, 2005, Pages 343-352

  Ibrahim, Ezzeldin M ^a   Ezzat, Adnan A ^b   Rahal, Mohammed M ^a   Raja, Madras M ^a   Ajarim, Dahish S ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^b NONE

Author keywords

Adjuvant chemotherapy; Breast cancer; Saudi Arabia

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PACLITAXEL; TAMOXIFEN; ANTINEOPLASTIC AGENT; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ADULT; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; DISEASE SEVERITY; EARLY CANCER; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SAUDI ARABIA; SURVIVAL TIME; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BREAST TUMOR; MIDDLE AGED; MORTALITY; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FLUOROURACIL; HUMANS; METHOTREXATE; MIDDLE AGED; PACLITAXEL; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; SAUDI ARABIA; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TREATMENT OUTCOME;

EID: 33644840237     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/MO:22:4:343     Document Type: Article

References (30)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics 1996. Ca-A Cancer J Clin 1996;46:5-27.
2. Parkin DM, Muir CS, Whelan SL, Gao Y-T, Ferlay F, Powell J (eds.). Cancer incidence in five continents, vol 6. IARC Scientific Publication no. 120. IARC, Lyon France, 1992.
3. Mahboubi E. Epidemiology of cancer in Saudi Arabia, 1975-1985. Ann Saudi Med 1987;7:265-276.
4. Ezzat A, et al. An overview of breast cancer. Ann Saudi Med 1997;17:10-15.
5. Al-Tamimi T, et al. Cancer in the eastern region of Saudi Arabia: a population-based study (1987-1988). Ann Saudi Med 1997;17:53-66.
6. Omer YT, Gjorgov AN, Ismail AS, Tabik MA. Cancer trends in Kuwait (1974-1982). In: M. Khogali, YT Omer, A Gjorgov, and AS Ismail (eds.). Cancer Prevention in Developing Countries. Pergamon, London, 1986, pp. 25-34.
7. Elston CW, Ellis IO. Pathological prognostic factor in breast cancer: experience from a larger study with long-term follow-up. Histopathology 1991;19:403-410.
8. Harmanek P, Sobin LH: TNM Classification of Malignant Tumors. UICC International Union Against Cancer. Springer-Verlag, Berlin, Germany, 1987.
9. American Joint Committee on Cancer: Manual for Staging of Cancer, 4th ed. Lippincott, Philadelphia, PA, 1992, pp. 149-154.
10. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Amer Statist Assoc 1958;53:457-481.
11. Brookmeyer R, Crowley J. A confidence interval for the median survival time. Biometrics 1982;38:29-41.
12. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-170.
13. Cox DR, Oakes D. Regression models and life tables (with discussion). J Roy Statist Soc 1997;B34:187-220.
14. Marubini E, Valsecchi MG: Analysing Data from Clinical Trials and Observational Studies. Wiley, New York, NY, 1995.
15. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. Wiley, New York, 1980.
16. Kay R. Proportional hazard regression models and the analysis of censored survival data. Appl Statist 1977;26:227-237.
17. Lacey JV Jr., Devesa SS, Brinton LA. Recent trends in cancer incidence and mortality. Environ Mol Mutagen 2002;39:82-88.
18. Gebauer G, Fehm T, Lang N, Jäger W. Tumor size, axillary lymph node status and steroid receptor expression in breast cancer: prognostic relevance 5 years after surgery. Breast Cancer Res Treat 2002;75:167-173.
19. Rouzier R, et al. Primary chemotherapy for operable breast cancer: incidence and prognostic significance of ipsilateral breast tumor recurrence after breast-conserving surgery. J Clin Oncol 2001;15:3828-3835.
20. Pratap R, Shousha S. Breast carcinoma in women under the age of 50: relationship between p53 immunostaining, tumor grade, and axillary lymph node status. Br Cancer Res Tret 1998;49:35-39.
21. Sant M, et al. Survival of women with breast cancer in Europe: variation with age, year of diagnosis and country. The Eurocare working group. Int J Cancer 1998;77:679-683.
22. Coleman M, et al. Cancer Survival in England and Wales, 1971-1995: Deprivation and NHS Region. The Stationery Office, London, 1999, p. 695.
23. Grosclaude P, et al. Survival of women with breast cancer in France: variation with age, stage and treatment. Br Cancer Res Treat 2001;70:137-143.
24. Fisher B, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16:2672-2685.
25. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001;30:96-102.
26. Early Breast Cacer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992;339:71-85.
27. Heimann R, et al. Angiogenesis as a predictor of long-term survival for patients with node-negative breast cancer. J Natl Cancer Inst 1996;88:1764-1769.
28. Weidner N, et al. Tumor angiogenesis and metastasis: Correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
29. Gasparini G, et al. Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol 1994;12:454-466.
30. Voogd AC, et al. Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol 2001;19:1688-1697.